お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
625192

ヒト免疫不全ウイルス (HIV):市場競争環境

Human Immunodeficiency Virus (HIV): Competitive Landscape to 2026

出版日: | 発行: GlobalData | ページ情報: 英文 52 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
ヒト免疫不全ウイルス (HIV):市場競争環境
出版日: 2018年02月28日
発行: GlobalData
ページ情報: 英文 52 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、HIV (ヒト免疫不全ウイルス) の治療薬の治験・上市の見通しについて分析し、治験の全体的な進展状況 (地域別の内訳、初期/後期段階にある製品、主なスポンサーなど) や、主要なパイプライン製品の治験動向 (治験段階別)、今後の市場規模の予測値、現在/将来の代表的企業の概略、今後の市場動向の見通しなどを調査しております。

第1章 序論

第2章 エグゼクティブ・サマリー

第3章 イントロダクション

  • 分析範囲
  • 疾患の概要と疫学

第4章 パイプライン製品の評価

  • パイプライン製品の概要
  • パイプライン製品:国/地域別の内訳
  • パイプライン製品:分子の種類別/標的別の内訳
  • パイプライン製品:指定薬の治験動向
  • パイプライン製品:治験中の製品

第5章 治験の評価

  • 治験の概要
  • 治験:HIVの治験の大手スポンサー
  • 治験:地域別の内訳
  • 治療領域の見通し
  • 参加率の分析

第6章 商業面での評価

  • 主な上市済み製品
  • 現在/将来の企業

第7章 競争環境の分析 (通算11年間分)

  • イベントの分類:概要
  • 米国
  • 欧州主要5ヶ国 (5EU)
  • 日本
  • ブラジル
  • 中国

第8章 付録

目次
Product Code: GDHC003CL

Human immunodeficiency virus (HIV) is a retrovirus that impairs and destroys the host's immune system, specifically targeting CD4 cells. Once an infected person has a CD4 cell count of less than 200 cells/μL, HIV has developed into acquired immunodeficiency syndrome (AIDS).The pipeline HIV features 443 products across all stages of clinical development, with small molecules prominently featured in Phase III. Vaccines, synthetic peptides, and monoclonal antibodies (mAbs) dominate the early-stage pipeline.

HIV is the most investigated indication within infectious diseases with 5,098 clinical trials, followed by hepatitis C (3,090) and hepatitis B (1,709). The analysis is based on clinical trials initiated from 1995 to the current date.

Overall, GlobalData expects new drug approvals to drive HIV market growth over the next decade (2016-2026).In particular, it provides an in-depth analysis of the following -

  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment: leading marketed products, current and future players
  • Competitive Landscape Analysis: key market events (2016-2026)

Companies mentioned in this report: Gilead Sciences, ViiV Healthcare, GlaxoSmithKline, Pfizer, Shionogi, Janssen (Johnson & Johnson), Bristol-Myers Squibb, Merck & Co, AbbVie, TaiMed Biologics, Theratechnologies, CytoDyn, Torii Pharmaceuticals, Japan Tobacco, Frontier Biotechnologies.

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -

  • Pipeline Assessment-regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment-trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment-leading marketed products, current and future players
  • Competitive Landscape Analysis-key market events (2016-2026).

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global HIV market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HIV market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

  • 1. Preface 2
  • 1.1 Table of Contents 2
  • 1.2 Abbreviations 3
  • 1.3 Related Reports 4
  • 1.4 Upcoming Related Reports 5
  • 2. Executive Summary 6
  • 2.2 Key Findings 7
  • 2.2 Key Events 8
  • 3. Introduction 9
  • 3.1 Report Scope 10
  • 3.2 Disease Overview and Epidemiology 12
  • 4. Pipeline Assessment 15
  • 4.1 Pipeline Overview 16
  • 4.2 Pipeline Breakdown by Region/Country 18
  • 4.3 Pipeline Breakdown by Molecule Type and Target 19
  • 4.4 Drug Review Designations 20
  • 4.5 Products in Clinical Development 21
  • 5. Clinical Trial Assessment 23
  • 5.1 Clinical Trials Overview 24
  • 5.2 Top Sponsors of Clinical Trials in HIV 25
  • 5.3 Trial Breakdown by Region 27
  • 5.4 Therapy Area Perspective 28
  • 5.5 Enrollment Analytics 29

6 Commercial Assessment 32

  • 6.1 Leading Marketed Products 33
  • 6.2 Current & Future Players 34
  • 7. Competitive Landscape Analysis (2016-2026) 35
  • 7.1 Events Classification Overview 36
  • 7.2 US 37
  • 7.3 5EU 38
  • 7.4 Japan 39
  • 7.5 Brazil 40
  • 7.6 China 41

8 Appendix 42

  • 8.1 Sources 43
  • 8.2 Methodology 45
  • 8.3 Key Events Included in the Analysis 46
  • 8.4 About the Authors 47
  • 8.5 About GlobalData 50
  • 8.6 Disclaimer 52
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.